Attached files

file filename
EX-99.1 - HCI VIOCARE SIGNS LEASE ON PREMISES IN GLASGOW FOR ITS FIRST VIOCARE CENTRE - Rafina Innovations Inc.ex991.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): March 1, 2015
 
HCi Viocare
Exact name of registrant as specified in its charter

Nevada
000-53089
30-0428006
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

 
Centrum Office, 38 Queen Street, Glasgow
 
G1 3DX
(Address of principal executive offices)
(Zip Code)

+44 141 548 8000
Registrant’s telephone number, including area code
 
 
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
1

 

SECTION 8.01   OTHER EVENTS

On March 2, 2015 the Company annouced  that the HCi Viocare group has entered into a lease agreement  for a modern, stand-alone 5,300 square foot facility in Glasgow, Scotland with an entry date of 1 March, 2015.
 
The building will host the Company’s first Viocare centre, a full service Prosthetic and Orthotic (“P&O”) practice with a superior standard of personalised care, due to open in the second quarter of 2015. This new facility will serve as the centre of reference and training for the intended chain of Viocare P&O and diabetic foot centres across Europe, ensuring their adherence to British and International standards.
 
The Company’s Technologies subsidiary will occupy the first floor of the building to continue to develop its portfolio of bioengineering innovations.
 
A copy of the Company’s news release is attached as an exhibit to this report.

SECTION 9.   FINANCIAL STATEMENTS AND EXHIBITS

9.01 Financial Statements and Exhibits

 (d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K:
 
Exhibit No.
Description
 
99.1
HCi Viocare signs lease on premises in Glasgow for its first Viocare centre
Filed herewith

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 
HCi VioCare
   
Dated: March 3, 2015
 By:
/s/ Sotirios Leontaritis
 
 Name:
Sotirios Leontaritis
 
 Title:
President, Treasurer, CEO, and Director


 

 

 
2